Moderna’s enormous coronavirus vaccine Phase III trial will start next month


Biotech company Moderna said on Thursday that it is going to start the Phase III trial of its experimental coronavirus vaccine with 30,000 volunteers next month.

The vaccine, known as mRNA-1273, will be given in the 100 microgram dose level in the trial, which is being done in conjunction with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

At that dose level, the company said it can deliver 500 million doses per year and perhaps as many as 1 billion doses per year starting in 2021, as it works with Swiss drugmaker Lonza for its manufacturing needs.

“We look forward to beginning our Phase 3 study of mRNA-1273 with some 30,000 participants in July,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna, in a statement. “Moderna is committed to advancing the clinical development of mRNA-1273 as safely and quickly as possible to demonstrate our vaccine’s ability to significantly reduce the risk of COVID-19 disease.”

The primary goal of the Phase III study is to prevent symptomatic COVID-19, with secondary goals including preventing severe COVID-19 (patients who need to be hospitalized) and preventing the infection of SARS-CoV-2, the virus that causes COVID-19. US SPREAD GOOD NEWS!

I run this site in my spare time and thoroughly enjoy giving you all positive news!  If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.